#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myasthenia gravis B-cell small lymphocytic lymphoma Neuroendocrine carcinoma metastatic Chondrodystrophy Idiopathic pulmonary fibrosis Hepatocellular carcinoma Prolymphocytic leukaemia Neuromyelitis optica spectrum disorder Non-Hodgkin's lymphoma unspecified histology indolent Progressive supranuclear palsy Restless legs syndrome Gaucher's disease type III Depression Vascular malformation Mitochondrial DNA depletion More trials…

    Learn about Rare Diseases

    Lennox-Gastaut syndrome – Treatment Ewing’s sarcoma – Basic Information SAPHO syndrome – Treatment Pituitary-dependent Cushing’s syndrome – Diagnostics Epidermolysis bullosa – Diagnostics Systemic mastocytosis – Treatment Shprintzen-Goldberg syndrome – Life with Disease Acute respiratory distress syndrome – Trials in Disease Short-bowel syndrome – Treatment Atypical haemolytic uraemic syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vaborbactam Nilotinib Ulotaront Escitalopram Riboflavin Bp Burfiralimab Glucose Monohydrate Ph. Eur. Metronidazole Sodium Chloride Ph. Eur. Dapirolizumab Pegol Tiotropium Bromide Monohydrate LUMC-BOB1-B7-TCR.1 Specific Nucleic Acid Sna-Her2 Ixazomib Citrate Isoprenaline Hydrochloride Eprosartan Mesilate Rbl012.2 Vesleteplirsen Pp1493 Levoleucovorin Disodium More therapies…

    Learn about Your Condition

    Amnestic disorder Alcohol use disorder Altered state of consciousness Myelofibrosis Intestinal ischaemia Stomatitis Ataxia telangiectasia Osteosarcoma Optic glioma Immunosuppression Hyperoxaluria Fragile X syndrome K-ras gene mutation Cervix carcinoma recurrent Eyelid ptosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Glioblastoma multiforme

  • Study on How Bevacizumab Affects the Immune System in Patients with Glioblastoma Multiforme

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Glioblastoma multiforme
    Investigated Drugs:
    • Bevacizumab
    Hungary

  • Long-term safety study of Temferon (modified stem cells with interferon-α2) in patients previously treated for glioblastoma multiforme

    Recruiting

    1 1 1
    Investigated Diseases:
    • Glioblastoma multiforme
    Investigated Drugs:
    • Autologous Cd34+ Haematopoietic Stem And Progenitor Cells Transduced With A Lentiviral Vector Encoding The Interferon Alpha-2 Gene
    Italy

  • Study on the Effects of Dendritic Cell Immunotherapy and Temozolomide in Patients with Glioblastoma

    Recruiting

    4 1 1
    Investigated Diseases:
    • Glioblastoma multiforme
    • Glioblastoma
    Investigated Drugs:
    • Temozolomide
    Norway

  • Study on the Safety and Effectiveness of Nivolumab, Ipilimumab, and Myeloid Dendritic Cells for Patients with Recurrent Glioblastoma After Surgery

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Glioblastoma multiforme
    • Glioblastoma
    Investigated Drugs:
    • Cd1C+/Cd141+ Myeloid Dendritic Cells Isolated From Peripheral Blood Mononuclear Cells
    • Relatlimab
    • Ipilimumab
    Belgium

  • MRI Study with Hyperpolarized Pyruvate for Patients with Glioblastoma

    Recruiting

    2 1 1
    Investigated Diseases:
    • Glioblastoma multiforme
    • Neoplasm malignant
    Investigated Drugs:
    • Pyruvic Acid
    Denmark

  • Study on LSTA1 and Temozolomide for Patients with Newly Diagnosed Glioblastoma Multiforme

    Recruiting

    2 1 1
    Investigated Drugs:
    • Lsta1
    • Temozolomide
    Estonia Latvia Lithuania
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!